|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.56 EUR | +0.54% |
|
-6.82% | -10.69% |
| 04/08 | European Stocks Close Higher Tuesday on Earnings Strength, Hormuz Talks | MT |
| 04/08 | Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader | MT |
| Market Cap | 8.91TCr 10TCr 8.31TCr 7.63TCr 14TCr 9,76400Cr 15TCr 98TCr 38TCr 4,88100Cr 39TCr 38TCr 16,17200Cr | P/E 2026 * |
12.2x | P/E 2027 * | 10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 10TCr 12TCr 9.37TCr 8.61TCr 16TCr 11,00900Cr 16TCr 1,10500Cr 43TCr 5,50300Cr 43TCr 43TCr 18,23400Cr | EV / Sales 2026 * |
2.12x | EV / Sales 2027 * | 1.91x |
| Free-Float |
89.21% | Yield 2026 * |
5.7% | Yield 2027 * | 6.05% |
Last Transcript: Sanofi
| 1 day | +0.61% | ||
| 1 week | -6.82% | ||
| 1 month | -2.15% | ||
| 3 months | -5.23% | ||
| 6 months | -9.45% | ||
| Current year | -10.69% |
| 1 week | 72.1 |  | 79.16 |
| 1 month | 72.1 | | 80.1 |
| Current year | 71.27 | | 84.9 |
| 1 year | 71.27 | | 93 |
| 3 years | 71.27 | | 111 |
| 5 years | 71.27 | | 111 |
| 10 years | 63.15 | | 111 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 57 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 65 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.54% | -6.82% | - | - | 10TCr | |
| -0.51% | -8.60% | +45.08% | +148.21% | 99TCr | |
| +0.20% | -4.42% | +49.05% | +50.81% | 61TCr | |
| -0.53% | -7.37% | +23.64% | +65.03% | 43TCr | |
| +0.48% | -2.77% | +40.27% | +34.96% | 35TCr | |
| +0.08% | -4.45% | +31.74% | +39.89% | 29TCr | |
| +2.09% | -9.27% | +5.42% | +7.61% | 24TCr | |
| +1.75% | -8.29% | -1.73% | -42.05% | 21TCr | |
| +2.94% | -0.78% | +29.17% | +60.32% | 21TCr | |
| +3.13% | +0.69% | +18.11% | +71.90% | 17TCr | |
| Average | +1.12% | -5.02% | +26.75% | +48.52% | 39.09TCr | |
| Weighted average by Cap. | +0.73% | -5.89% | +33.77% | +70.63% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.75TCr 5.47TCr 4.43TCr 4.07TCr 7.69TCr 5,20400Cr 7.78TCr 52TCr 20TCr 2,60100Cr 21TCr 20TCr 8,61900Cr | 5.06TCr 5.83TCr 4.72TCr 4.34TCr 8.2TCr 5,54600Cr 8.29TCr 56TCr 22TCr 2,77200Cr 22TCr 21TCr 9,18600Cr |
| Net income | 769.18Cr 885.84Cr 717.16Cr 658.82Cr 1.25TCr 84TCr 1.26TCr 8.46TCr 3.31TCr 42TCr 3.33TCr 3.25TCr 1,39600Cr | 935.28Cr 1.08TCr 872.03Cr 801.09Cr 1.52TCr 1,02500Cr 1.53TCr 10TCr 4.02TCr 51TCr 4.05TCr 3.96TCr 1,69700Cr |
| Net Debt | 1.14TCr 1.31TCr 1.06TCr 973.63Cr 1.84TCr 1,24500Cr 1.86TCr 12TCr 4.88TCr 62TCr 4.92TCr 4.81TCr 2,06300Cr | 767.61Cr 884.04Cr 715.7Cr 657.48Cr 1.24TCr 84TCr 1.26TCr 8.44TCr 3.3TCr 42TCr 3.32TCr 3.25TCr 1,39300Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/26/31 | €74.16 | +1.87% | 8,353 |
| 04/26/04 | €74.32 | -0.40% | 3,409 |
| 03/26/03 | €74.62 | +0.62% | 4,864 |
| 31/26/31 | €74.16 | +1.87% | 8,353 |
| 30/26/30 | €72.80 | -8.86% | 16,594 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- 1SAN Stock
Select your edition
All financial news and data tailored to specific country editions
